Yes he is from Memorial Sloan Kettering and was on todays show and the interview was was very insightful worth looking at. 

I agree for once there was none of that over talking that they do.

http://www.youtube.com/watch?v=J71ff_1mAqI

Not a great fan of The View or Larry Norton, MD.  But above is a very recent Dr. Norton interview from MSK's website.  I question much of what he says particularly about Axillary Lymph Node Dissection AND SCREENING mammograms for certain populations....  Below is the most recent study from JAMA regarding ALND published months before the interview:

Original Contribution

JAMA. 2011;305(6):569-575. doi: 10.1001/jama.2011.90

Axillary Dissection vs No Axillary
Dissection in Women With Invasive Breast Cancer and Sentinel Node Metastasis

A Randomized Clinical Trial

1.  
Armando E.
Giuliano, MD;

2.  
Kelly K. Hunt,
MD;

3.  
Karla V. Ballman,
PhD;

4.  
Peter D. Beitsch,
MD;

5.  
Pat W. Whitworth,
MD;

6.  
Peter W.
Blumencranz, MD;

7.  
A. Marilyn
Leitch, MD;

8.  
Sukamal Saha,
MD;

9.  
Linda M. McCall,
MS;

10.  Monica Morrow,
MD

[+]
Author Affiliations

1. Author Affiliations: John Wayne Cancer Institute at Saint John's Health
Center, Santa Monica, California (Dr Giuliano); M. D. Anderson Cancer Center,
Houston, Texas (Dr Hunt); Mayo Clinic Rochester, Rochester, Minnesota (Dr
Ballman); Dallas Surgical Group, Dallas, Texas (Dr Beitsch); Nashville Breast
Center, Nashville, Tennessee (Dr Whitworth); Morton Plant Hospital, Clearwater,
Florida (Dr Blumencranz); University of Texas Southwestern Medical Center, Dallas
(Dr Leitch); McLaren Regional Medical Center, Michigan State University, Flint
(Dr Saha); American College of Surgeons Oncology Group, Durham, North Carolina
(Ms McCall); and Memorial Sloan-Kettering Cancer Center, New York, New York (Dr
Morrow).

Abstract

Context Sentinel lymph node dissection (SLND) accurately
identifies nodal metastasis of early breast cancer, but it is not clear whether
further nodal dissection affects survival.

Objective To determine the effects of complete axillary lymph
node dissection (ALND) on survival of patients with sentinel lymph node (SLN)
metastasis of breast cancer.

Design, Setting, and Patients The American College
of Surgeons Oncology Group Z0011 trial, a phase 3 noninferiority trial
conducted at 115 sites and enrolling patients from May 1999 to December 2004.
Patients were women with clinical T1-T2 invasive breast cancer, no palpable
adenopathy, and 1 to 2 SLNs containing metastases identified by frozen section,
touch preparation, or hematoxylin-eosin staining on permanent section. Targeted
enrollment was 1900 women with final analysis after 500 deaths, but the trial
closed early because mortality rate was lower than expected.

Interventions All patients underwent
lumpectomy and tangential whole-breast irradiation. Those with SLN metastases
identified by SLND were randomized to undergo ALND or no further axillary
treatment. Those randomized to ALND underwent dissection of 10 or more nodes.
Systemic therapy was at the discretion of the treating physician.

Main Outcome Measures Overall survival was
the primary end point, with a noninferiority margin of a 1-sided hazard ratio
of less than 1.3 indicating that SLND alone is noninferior to ALND.
Disease-free survival was a secondary end point.

Results Clinical and tumor characteristics were similar
between 445 patients randomized to ALND and 446 randomized to SLND alone.
However, the median number of nodes removed was 17 with ALND and 2 with SLND
alone. At a median follow-up of 6.3 years (last follow-up, March 4, 2010),
5-year overall survival was 91.8% (95% confidence interval [CI], 89.1%-94.5%)
with ALND and 92.5% (95% CI, 90.0%-95.1%) with SLND alone; 5-year disease-free
survival was 82.2% (95% CI, 78.3%-86.3%) with ALND and 83.9% (95% CI,
80.2%-87.9%) with SLND alone. The hazard ratio for treatment-related overall
survival was 0.79 (90% CI, 0.56-1.11) without adjustment and 0.87 (90% CI,
0.62-1.23) after adjusting for age and adjuvant therapy.

Conclusion Among patients with limited SLN metastatic breast
cancer treated with breast conservation and systemic therapy, the use of SLND
alone compared with ALND did not result in inferior survival.

Trial Registration clinicaltrials.gov
Identifier: NCT00003855

KEYWORDS:

 Regarding SCREENING mammography, you can read my comments and the accompanying studies on the Julianna Rancic thread....

I feel very strongly that we deserve better than listening to dogma from such an esteemed physician. My medical oncologist worked very closely with Dr. Norton on his game changing "dose dense" chemotherapy trial and he deserves to be commended for that idea since it has improved AND saved the lives of so many breast cancer patients.  However, as long as he remains firm in his ideas about other issues, it is going to be difficult to find even better methods of SCREENING and THERAPY.  Yes, SCREENING mammograms are important for women over between 50 and 69 years of age.  DIAGNOSITIC mammograms are important for ALL women.  But we need better SCREENING techniques for all of the sisters....especially for the younger women with dense breasts.  BTW....I was one of those women who went for annual SCREENING mammograms beginning at age 40.  Knew I had dense breasts and also had annual sonograms.  At age 53, my lump was found by my ob/gyn at my routine annual visit.  DIAGNOSTIC mammogram missed it.  Sonogram found it.   MRI found a drop of DCIS that both the mammogram and sonogram missed.  Go figure.

Regarding ALND...well, now we know that many women can forgo it.  Don't understand why he didn't mention that in his interview because it was already known......